舒肝益脾颗粒(无糖型)主要活性成分改善非酒精性脂肪性肝病的临床和实验研究

    Main Active Ingredients of Shugan Yipi Granule(Sugar-free Type) Improve Nonalcoholic Fatty Liver Disease Based on Clinical and Experimental Research

    • 摘要:
      目的 基于系统药理学、临床研究和体外试验探索舒肝益脾颗粒(无糖型)抗非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)的作用机制。
      方法 临床检测23例NAFLD患者用药后肝脏衰减指数、游离脂肪酸和血脂水平;血浆代谢组学检测患者入血成分和差异代谢物;TCMSP、GeneCards等数据库筛选药物成分和疾病靶点,蛋白-蛋白相互作用(protein-protein interaction,PPI)网络筛选核心靶点,根据药物-成分-靶点-通路-疾病网络图各节点的度值筛选主要活性成分;AutoDockTools对核心靶点和主要活性成分进行分子对接;结合网络药理学结果和文献分析,筛选出舒肝益脾颗粒(无糖型)主要活性成分槲皮素、山柰酚进行初步细胞验证试验。
      结果 网络药理学预测结果显示,舒肝益脾颗粒(无糖型)主要有效成分包括槲皮素、山柰酚等60种,核心靶点显著富集于PI3K-AKT信号通路。舒肝益脾颗粒(无糖型)临床疗效显示其能明显改善患者肝脏硬度和脂肪衰减,显著降低患者体内游离脂肪酸和血脂水平等;血浆代谢组学分析中,槲皮素和山柰酚是显著上调的差异代谢物。体外验证实验显示槲皮素、山柰酚能有效抑制细胞内脂肪酸摄取、减少NAFLD细胞模型中的脂质沉积,并降低三酰甘油(triglyceride,TG)含量,上调PI3K-AKT信号通路中p-PI3K/AKT、p-AKT/AKT的表达。
      结论 舒肝益脾颗粒(无糖型)对NAFLD患者肝脏脂质代谢有改善作用,槲皮素和山柰酚是舒肝益脾颗粒(无糖型)防治NAFLD的关键活性成分,PI3K-AKT信号通路是预测的主要信号通路。槲皮素、山柰酚可抑制游离脂肪酸诱导的HepG2细胞内脂肪酸摄取,降低NAFLD细胞模型内脂质积累和TG含量,其可能通过促进PI3K-AKT信号通路蛋白磷酸化缓解NAFLD。

       

      Abstract:
      OBJECTIVE To explore the mechanism of Shugan Yipi granules(sugar-free type) against nonalcoholic fatty liver disease(NAFLD) based on systematic pharmacology, clinical research and in vitro experiments.
      METHODS  The levels of liver attenuation index, free fatty acid and lipids in 23 patients with NAFLD were tested. Plasma metabolomics was used to detect the composition and differential metabolites of patients. Databases such as TCMSP and GeneCards were used to screen drug components and disease targets. The protein-protein interaction(PPI) network screened core targets, and the main active components were screened according to the degree values of each node in the drug-component-target-pathway-disease network. AutoDockTools performs molecular docking between the core target and the main active ingredients. Based on the results of network pharmacology and metabolic analysis, quercetin and kaempferol, the main active components of Shugan Yipi granules(sugar-free type), were selected for preliminary cell verification experiments.
      RESULTS  Network pharmacology prediction results showed that the main active components of Shugan Yigan granules(sugar-free type) included 60 types such as quercetin and kaempferol, and the core target was significantly enriched in the PI3K-AKT signaling pathway. The clinical effect of Shugan Yipi granules(sugar-free type) showed that it could significantly improve liver hardness and fat decay, and significantly reduce the levels of free fatty acids and lipids in patients. In plasma metabolomics analysis, quercetin and kaempferol were significantly upregulated by differential metabolites. The in vitro validation experiments showed that quercetin and kaempferol could effectively inhibit intracellular fatty acid uptake, reduce lipid deposition and triglyceride(TG) content in NAFLD cell models, and up-regulate the expression of p-PI3K/AKT and p-AKT/AKT in the PI3K-AKT signaling pathway.
      CONCLUSION  Shugan Yipi granules(sugar-free type) can improve liver lipid metabolism in patients with NAFLD. Quercetin and kaempferol are the key active ingredients of Shugan Yipi granules(sugar-free type) in the prevention and treatment of NAFLD, and the PI3K-AKT signaling pathway is the main signaling pathway predicted. Quercetin and kaempferol can inhibit fatty acid uptake in HepG2 cells induced by free fatty acids, reduce lipid accumulation and TG content in NAFLD cell model, and may alleviate NAFLD by promoting protein phosphorylation in PI3K-AKT signaling pathway.

       

    /

    返回文章
    返回